• Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited
• New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE’s efficacy and symptom improvements across the body in individuals with psoriasis
• Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis
• Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.